CoChat

Probiotics in the Management of Inflammatory Bowel Disease: A Systematic Review of Intervention Studies in Adult Patients

Open access

The DOI matches its Crossref record; 142 of the 142 references it cites were found in a registry or an index.

Abstract

Introduction Mounting evidence suggests an important role for the intestinal microbiota in the chronic mucosal inflammation that occurs in inflammatory bowel disease (IBD), and novel molecular approaches have further identified a dysbiosis in these patients. Several mechanisms of action of probiotic products that may interfere with possible aetiological factors in IBD have been postulated.Objective Our objective was to discuss the rationale for probiotics in IBD and to systematically review clinical intervention studies with probiotics in the management of IBD in adults.Methods A systematic search was performed in PubMed up to 1 October 2011, using defined keywords. Only full-text papers in the English language addressing clinical outcomes in adult patients were included. The 41 eligible studies were categorized on disease type (ulcerative colitis [UC] with/without an ileo-anal pouch and Crohn's disease [CD]) and disease activity. Pooled odds ratios were only calculated per probiotic for a specific patient group when more than one randomized controlled trial was available.Results Well designed randomized controlled trials supporting the application of probiotics in the management of IBD are still limited. Meta-analyses could only be performed for a limited number of studies revealing overall risk ratios of 2.70 (95% CI 0.47, 15.33) for inducing remission in active UC with Bifido-fermented milk versus placebo or no additive treatment (n = 2); 1.88 (95% CI 0.96, 3.67) for inducing remission in active UC with VSL#3 versus placebo (n = 2); 1.08 (95% CI 0.86, 1.37) for preventing relapses in inactive UC with Escherichia coli Nissle 1917 versus standard treatment (n = 3); 0.17 (95% CI 0.09, 0.33) for preventing relapses in inactive UC/ileo-anal pouch anastomosis (IPAA) patients with VSL#3 versus placebo; 1.21 (95% CI 0.57, 2.57) for preventing endoscopic recurrences in inactive CD with Lactobacillus rhamnosus GG versus placebo (n = 2); and 0.93 (95% CI 0.63, 1.38) for preventing endoscopic recurrences in inactive CD with Lactobacillus johnsonii versus placebo (n = 2).Conclusion Further well designed studies based on intention-to-treat analyses by several independent research groups are still warranted to support the promising results for E. coli Nissle in inactive UC and the multispecies product VSL#3 in active UC and inactive pouch patients. So far, no evidence is available to support the use of probiotics in CD. Future studies should focus on specific disease subtypes and disease location. Further insight into the aetiology of IBD and the mechanisms of probiotic strains will aid in selecting probiotic strains for specific disease entities and disease locations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2165/11632710-000000000-00000

Cites

142 of 142 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 142 references

Research works printed but not linked: 3

  1. Tursi, 2004 Nov, Med Sci Monit, 10, PI126
  2. Kuzela, 2001 Nov, Am J Gastroenterol, 96, 3218, 10.1111/j.1572-0241.2001.05294.x · doi:10.1111/j.1572-0241.2001.05294.x · Paper page
  3. Ulisse, 2001 Sep, Am J Gastroenterol, 96, 2691, 10.1111/j.1572-0241.2001.04139.x · doi:10.1111/j.1572-0241.2001.04139.x · Paper page

Cited by

See all 276

Metadata

Authors
Jonkers, D., Penders, J., Masclee, A., & Pierik, M.
Affiliations
Maastricht University Medical Centre (NL)
Corresponding author
Jonkers, Daisy
Venue
Drugs
Published
2012-04
Volume
72
Issue
6
Pages
803-823
ISSN
0012-6667 (ISSN-L)
OpenAlex
W1592603924
Cited by
240
References
142
Citations by year
2026: 5 · 2025: 11 · 2024: 15 · 2023: 5 · 2022: 20 · 2021: 8 · 2020: 10 · 2019: 17 · 2018: 8 · 2017: 20 · 2016: 21 · 2015: 23 · 2014: 37 · 2013: 30 · 2012: 10
FWCI
4.19
Type
journal article
Language
en
Open access
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
Topics
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
probiotics, inflammatory bowel disease, ulcerative colitis, Crohn's disease, gut microbiota, dysbiosis, VSL#3, Bifidobacterium, Lactobacillus rhamnosus GG, Lactobacillus johnsonii, Escherichia coli Nissle 1917, remission induction, relapse prevention, endoscopic recurrence, disease activity, adults, randomized controlled trials
MeSH terms
Adult, Humans, Remission Induction, Inflammatory Bowel Diseases, Randomized Controlled Trials as Topic, Treatment Outcome, Probiotics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Probiotics in the Management of Inflammatory Bowel Disease: A Systematic Review of Intervention Studies in Adult Patients. https://app.cochat.ai/papers/10.2165/11632710-000000000-00000
The paper
Jonkers, D., Penders, J., Masclee, A., & Pierik, M. (2012). Probiotics in the Management of Inflammatory Bowel Disease: A Systematic Review of Intervention Studies in Adult Patients. Drugs. https://doi.org/10.2165/11632710-000000000-00000

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.